newsfilter
← Latest News
PR Newswire·

VolitionRx Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in Cats

VNRX
  • VolitionRx Limited submitted a clinical manuscript for peer review regarding its Nu.Q® Vet Feline prototype assay.
  • The assay demonstrated 97% specificity and detected 86% of feline lymphoma cases, the most common cancer in cats.
  • The technology uses elevated H3.1-nucleosome levels as a biomarker to differentiate healthy cats from those with intermediate-large cell lymphoma.
  • Publication in a peer-reviewed journal is expected to unlock a $5 million contractual milestone payment.
  • The Nu.Q® Vet Feline Test aims to double Volition's total addressable market in the companion animal space by adding a feline equivalent to its existing canine test.
  • The Nu.Q® Vet Canine test is currently available in more than 20 countries.
  • There are approximately 73.8 million pet cats in the U.S., with an estimated 1 in 5 developing cancer in their lifetime.
  • Over 25% of U.S. cats are seniors (aged 8+), creating a recurring screening opportunity for over 18 million pets.
  • The North American veterinary oncology market is projected to reach $1.77 billion by 2025, with the feline segment expected to grow faster than the canine segment.
  • The study paper will be available on a preprint service in the coming days.
  • Volition plans to commercialize the test through reference laboratories and point-of-care platforms following product development completion.